MRC / AstraZeneca Small Molecule High Throughput Screen
Funds public-private screening work in the United Kingdom through partnerships for small molecule exploration.
This MRC/AstraZeneca partnership grant funds researchers to conduct small-molecule high-throughput screens (HTS) using AstraZeneca's compound library and facilities. Up to 4 projects funded annually; maximum award £270K per project (£1M total pool). Duration 12–18 months. Split funding: AstraZeneca covers assay optimisation and HTS execution (£170K, 100% fEC); host institution costs cover researcher visits and confirmatory assays (up to £100K, 80% fEC).
BiotechMedtech
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.